Browse > Article

In Vitro Study of Tumor Seeking Radiopharmaceutical Uptake by Human Breast Cancer Cell Line MCF-7 after Paclitaxel Treatment  

Choi, Joon-Young (Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Choi, Yong (Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Choe, Yearn-Seong (Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Lee, Kyung-Han (Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Kim, Byung-Tae (Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Publication Information
Nuclear Medicine and Molecular Imaging / v.41, no.5, 2007 , pp. 364-372 More about this Journal
Abstract
Purpose: This study was designed to investigate the cellular uptake of various tumor imaging radiopharmaceuticals in human breast cancer cells before and after paclitaxel exposure considering viable cell number. Materials and Methods: F-18-fluorodeoxyglucose, C-11-methionine, Tl-201, Tc-99m-MIBI, and Tc-99m-tetrofosmin were used to evaluate the cellular uptake in MCF-7 cells. MCF-7 cells were cultured in multi-well plates. Wells were divided into DMSO exposure control group, and paclitaxel exposure group. The exposure durations of paclitaxel with 10 nM or 100 nM were 2 h, 6 h, 12 h, 24 h, and 48 h. Results: Viable cell fraction was reduced as the concentration and exposure time of paclitaxel increased. After 10 nM paclitaxel exposure, the cellular uptake of all 5 radiopharmaceuticals was not reduced significantly, irrespective of exposure time and viable cell fraction. After 100 nM paclitaxel exposure, the cellular uptake of all 5 radiopharmaceuticals was enhanced significantly irrespective of viable cell fraction. The peak uptake was observed in experimental groups with paclitaxel exposure for 6 to 48 h according the type of radiopharmaceutical. When the cellular uptake was adjusted for the viable cell fraction and cell count, the peak cellular uptake was observed in experimental groups with paclitaxel exposure for 48 h, irrespective of the type of radiopharmaceutical. Conclusion: The cellular uptake of F-18-fluorodeoxyglucose, C-11-methionine, Tl-201, Tc-99m-MIBI, and Tc-99m-tetrofosmin did not reflect viable cell number in MCF-7 cells after paclitaxel exposure for up to 48 h.
Keywords
F-18-fluorodeoxyglucose; C-11-methionine; TI-201; Tc-99m-MIBI; Tc-99m-tetrofosmin; paclitaxel; MCF-7; breast cancer; cell viability;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Kao CH, Hsieh JF, Tsai SC, Ho YJ, Changlai SP, Lee JK. Paclitaxel-based chemotherapy for non-small cell lung cancer: predicting the response with 99mTc-tetrofosmin chest imaging. J Nucl Med 2001;42:17-20
2 Haberkorn U, Oberdorfer F, Klenner T, Strauss LG, Stohr M, Wallich R, et al. Metabolic and transcriptional changes in osteosarcoma cells treated with chemotherapeutic drugs. Nucl Med Biol 1994;21:835-45   DOI   ScienceOn
3 Yang DJ, Azhdarinia A, Wu P, Yu DF, Tansey W, Kalimi SK, et al. In vivo and in vitro measurement of apoptosis in breast cancer cells using 99mTc-EC-annexin V. Cancer Biother Radio 2001; 16:73-83   DOI   ScienceOn
4 Haberkorn U, Altmann A, Kamencic H, Morr I, Traut U, Henze M, et al. Glucose transport and apoptosis after gene therapy with HSV thymidine kinase. Eur J Nucl Med 2001;28:1690-6   DOI   ScienceOn
5 Chung JK, Kim YK, Kim SK, Lee YJ, Paek S, Yeo JS, et al. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol I 2002;29:176-82   DOI   ScienceOn
6 Fukumoto M, Kurohara A, Yoshimura N, Yoshida D, Akagi N, Yoshida S. Relationship between ATP synthesis and 201Tl uptake in transformed and non-transformed cell lines. Nucl Med Commun 1998;19:1169-75   DOI   ScienceOn
7 Leyton J, Latigo JR, Perumal M, Dhaliwal H, He Q, Aboagye EO. Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res 2005;65:4202-10   DOI   ScienceOn
8 Minn H, Clavo AC, Wahl RL. Influence of hypoxia on tracer accumulation in squamous-cell carcinoma: in vitro evaluation for PET imaging. Nucl Med Biol 1996;23:941-6   DOI   ScienceOn
9 Clavo AC. Wahl RL. Effects of hypoxia on the uptake of tritiated thymidine, L-leucine, L-methionine and FDG in cultured cancer cells. J Nucl Med 1996;37:502-6
10 Brucher BL, Weber W, Bauer M, Fink U, Avril N, Stein HJ, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 2001;233:300-9   DOI   ScienceOn
11 Haberkorn U, Morr I, Oberdorfer F, Bellemann ME, Blatter J, Altmann A, et al. Fluorodeoxyglucose uptake in vitro: aspects of method and effects of treatment with gemcitabine. J Nucl Med 1994;35:1842-50
12 Tian M, Zhang H, Nakasone Y, Mogi K, Endo K. Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study. Eur J Nucl Med Mol I 2004;31:5-12   DOI
13 Furuta M, Nozaki M, Kawashima M, Iimuro M, Okayama A, Fukushima M, et al. Monitoring mitochondrial metabolisms in irradiated human cancer cells with 99mTc-MIBI. Cancer Lett 2004; 212:105-11   DOI   ScienceOn
14 Fuster D, Vinolas N, Mallafre C, Pavia J, Martin F, Pons F. Tetrofosmin as predictors of tumour response. Q J Nucl Med 2003; 47:58-62
15 Shih CM, Hsu WH, Huang WT, Wang JJ, Ho ST, Kao A. Usefulness of chest single photon emission computed tomography with technetium-99m methoxyisobutylisonitrile to predict taxol based chemotherapy response in advanced non-small cell lung cancer. Cancer Lett 2003;199:99-105   DOI   ScienceOn
16 Slosman DO, Pugin J. Lack of correlation between tritiated deoxyglucose, thallium-201 and technetium-99m-MIBI cell incorporation under various cell stresses. J Nucl Med 1994;35:120-6
17 Sato T, Indo H, Kawabata Y, Kobayashi T, Suenaga S, Iwashita Y, et al. Thallium-201 chloride (Tl-201) accumulation and Na+/K+-ATPase expression in tumours of the head and neck. Dentomaxillofac Rad 2005;34:212-7   DOI   ScienceOn
18 Yeo JS, Lim SJ, Oh SJ, Ryu JS, Yun MK, Moon DH. Comparison of F-18 FLT uptake with F-18 FDG for early evaluation of chemotherapy response in human cancer cell lines. J Nucl Med 2003;44:81P [Abstract]
19 Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972-80
20 Maini CL, Tofani A, Sciuto R, Semprebene A, Cavaliere R, Mottolese M, et al. Technetium-99m-MIBI scintigraphy in the assessment of neoadjuvant chemotherapy in breast carcinoma. J Nucl Med 1997;38:1546-51
21 Olah E, Csokay B, Prajda N, Kote-Jarai Z, Yeh YA, Weber G. Molecular mechanisms in the antiproliferative action of taxol and tiazofurin. Anticancer Res 1996;16:2469-77
22 Chung JK, Lee YJ, Kim C, Choi SR, Kim M, Lee K, et al. Mechanisms related to [18F]fluorodeoxyglucose uptake of human colon cancers transplanted in nude mice. J Nucl Med 1999; 40:339-46
23 Brown RS, Leung JY, Kison PV, Zasadny KR, Flint A, Wahl RL. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med 1999;40:556-65
24 Ishiwata K, Kubota K, Murakami M, Kubota R, Sasaki T, Ishii S, et al. Re-evaluation of amino acid PET studies: can the protein synthesis rates in brain and tumor tissues be measured in vivo?. J Nucl Med 1993;34:1936-43
25 Kinuya S, Yokoyama K, Li XF, Bai J, Watanabe N, Shuke N, et al. Hypoxia-induced alteration of tracer accumulation in cultured cancer cells and xenografts in mice: implications for pre-therapeutic prediction of treatment outcomes with 99mTc-sestamibi, 201Tl chloride and 99mTc-HL91. Eur J Nucl Med Mol I 2002;29:1006-11   DOI   ScienceOn
26 Ishiwata K. Vaalburg W. Elsinga PH. Paans AM. Woldring MG. Comparison of L-[1-11C]methionine and L-methyl-[11C]methionine for measuring in vivo protein synthesis rates with PET. J Nucl Med 1988;29:1419-27
27 Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 1995;36:1625-32
28 Zhao S, Kuge Y, Mochizuki T, Takahashi T, Nakada K, Sato M, et al. Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. J Nucl Med 2005;46:675-82
29 Higashi K, Clavo AC, Wahl RL. In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. J Nucl Med 1993;34:773-9
30 Arbab AS, Koizumi K, Toyama K, Araki T. Uptake of technetium-99m-tetrofosmin, technetium-99m-MIBI and thallium-201 in tumor cell lines. J Nucl Med 1996;37:1551-6
31 Chang YF, Renshaw HW. Pasteurella haemolytica leukotoxin: comparison of 51chromium-release, trypan blue dye exclusion, and luminol-dependent chemiluminescence-inhibition assays for sensitivity in detecting leukotoxin activity. Am J Vet Res 1986;47:134-8
32 Del Vecchio S, Salvatore M. 99mTc-MIBI in the evaluation of breast cancer biology. Eur J Nucl Med Mol I 2004;31(Suppl 1):S88-96   DOI   ScienceOn
33 Rozental JM, Levine RL, Nickles RJ, Dobkin JA. Glucose uptake by gliomas after treatment. A positron emission tomographic study. Arch Neurol 1989;46:1302-7   DOI   ScienceOn
34 Tohma T, Okazumi S, Makino H, Cho A, Mochiduki R, Shuto K, et al. Relationship between glucose transporter, hexokinase and FDG-PET in esophageal cancer. Hepato-Gastroenterol 2005;52:486-90
35 Belhocine T, Steinmetz N, Hustinx R, Bartsch P, Jerusalem G, Seidel L, et al. Increased uptake of the apoptosis-imaging agent 99mTc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res 2002;8:2766-74
36 Zor T, Selinger Z. Linearization of the Bradford protein assay increases its sensitivity: theoretical and experimental studies. Anal Biochem 1996;236:302-8   DOI   ScienceOn
37 Been LB, Suurmeijer AJ, Cobben DC, Jager PL, Hoekstra HJ, Elsinga PH. [18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol I 2004;31:1659-72   DOI   ScienceOn
38 Murata H, Kusuzaki K, Takeshita H, Hirata M, Hashiguchi S, Emoto K, et al. Assessment of chemosensitivity in patients with malignant bone and soft tissue tumors using thallium-201 scintigraphy and doxorubicin binding assay. Anticancer Res 2000;20:3967-70
39 Haberkorn U, Reinhardt M, Strauss LG, Oberdorfer F, Berger MR, Altmann A, et al. Metabolic design of combination therapy: use of enhanced fluorodeoxyglucose uptake caused by chemotherapy. J Nucl Med 1992;33:1981-7
40 Charles AG, Han TY, Liu YY, Hansen N, Giuliano AE, Cabot MC. Taxol-induced ceramide generation and apoptosis in human breast cancer cells. Cancer Chemoth Pharm 2001;47:444-50   DOI
41 Chesnay E, Babin E, Constans JM, Agostini D, Bequignon A, Regeasse A, et al. Early response to chemotherapy in hypopharyngeal cancer: assessment with 11C-methionine PET, correlation with morphologic response, and clinical outcome. J Nucl Med 2003; 44:526-32